June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Long-term real world outcomes in younger (under 60yrs) patients receiving anti-VEGF therapy for choridal neovascular membrane (CNVM).
Author Affiliations & Notes
  • Lyudmila Kishikova
    Ophthalmology, Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Yewande Babalola
    Ophthalmology, Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Maged S Habib
    Ophthalmology, Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Deepali Varma
    Ophthalmology, Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • David Steel
    Ophthalmology, Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Jonathan Smith
    Ophthalmology, Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Maria T Sandinha
    Ophthalmology, Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Ajay Kumar Kotagiri
    Ophthalmology, Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Footnotes
    Commercial Relationships   Lyudmila Kishikova, None; Yewande Babalola, None; Maged Habib, Bayer (R), Novatis (R); Deepali Varma, Bayer (R), Novatis (R); David Steel, Bayer (R), Novatis (R); Jonathan Smith, Bayer (R), Novatis (R); Maria Sandinha, Bayer (R); Ajay Kumar Kotagiri, Bayer (R)
  • Footnotes
    Support  Travel grants from Bayer and Novartis
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 418. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Lyudmila Kishikova, Yewande Babalola, Maged S Habib, Deepali Varma, David Steel, Jonathan Smith, Maria T Sandinha, Ajay Kumar Kotagiri; Long-term real world outcomes in younger (under 60yrs) patients receiving anti-VEGF therapy for choridal neovascular membrane (CNVM).. Invest. Ophthalmol. Vis. Sci. 2017;58(8):418.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionised the management of CNVM due to neovascular Age related Macular Degeneration (nAMD), myopic macular degeneration as well as secondary causes. However no long-term real life data is available with regard to their effectiveness in myopic CNVM, nAMD and secondary CNVM diagnosed in younger age group (<60 years).
The aim of the project is to evaluate the visual and anatomical outcomes in younger (<60 years) patients with CNVM receiving intra-vitreal anti-VEGF therapy.

Methods : Retrospective audit of consecutive younger patients (<60yrs), receiving intra-vitreal anti-VEGF injections for the treatment of CNVM between January 2014 and January 2016 at a single regional centre (Sunderland Eye Iinfirmary).Visual acuity, OCT features, follow up period and number of treatments received was noted.

Results : 65 eyes receiving treatment for nAMD, myopic CNVM and secondary CNVM were included. Mean age of patients was 52 years. Diagnosis of nAMD was made in 50.77% of eyes, Myopic CNVM in 24.62% and secondary CNVM in 24.62 eyes. Mean follow up period was 29.1 months. Visual acuity stabilised in 80% of patients with 15.4% gaining >15 letters. On average, patients received 8.5 injections. There was significant reduction in the central macular thickness (mean change of -68.5 um) with 37.9% being dry on OCT at last follow up.

Conclusions : This audit confirmed the effectiveness of anti VEGF therapy in younger age group diagnosed with CNVM. Limitations include small number of patients and varied follow up.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×